Building on this foundation, this review aims to focus on six representative MetAP2 inhibitors with preclinical or clinical research outcomes for type 2 diabetes and obesity, exploring their mechanisms of action, therapeutic potential, and results from these studies. Here, METAP2 is linked to obesity disorder.